Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.48 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22690656 | 1.00 | CTSK (0.50) | CTSKCTSSCTSBCYP26A1CTSA | |
| SCHEMBL740964 | 1.00 | CTSK (0.50) | CTSKCTSSCTSBCYP26A1CTSA | |
| SCHEMBL29861162 | 0.89 | CTSS (0.47) | CTSKCTSSCTSBCYP26A1AAK1 | |
| SCHEMBL21459379 | 0.89 | CTSS (0.47) | CTSKCTSSCTSBCYP26A1AAK1 | |
| SCHEMBL21459378 | 0.89 | CTSS (0.47) | CTSKCTSSCTSBCYP26A1AAK1 | |
| SCHEMBL27351850 | 0.89 | CTSS (0.47) | CTSKCTSSCTSBCYP26A1AAK1 | |
| SCHEMBL4838536 | 0.87 | CTSS (0.49) | CTSKCTSSCTSBAAK1ALDH1A1 | |
| SCHEMBL29676847 | 0.87 | CTSS (0.49) | CTSKCTSSCTSBAAK1ALDH1A1 | |
| SCHEMBL4704028 | 0.87 | CTSS (0.49) | CTSKCTSSCTSBAAK1ALDH1A1 | |
| SCHEMBL4838542 | 0.87 | CTSS (0.49) | CTSKCTSSCTSBAAK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| CN-117642396-A | Alpha V beta 6 and alpha V beta 1 integrin inhibitors and uses thereof | 戴斯分子SV有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-4304716-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | Dice Molecules Sv, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3972590-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | Merck Sharp & Dohme Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-112312910-A | Human integrin alpha 4 beta 7 antagonists | 莫菲克医疗股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2020236688-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20040010023-A1 | Biphenyl derivatives and the use thereof as integrin inhibitors | MERCK PATENT GMBH (DE) | 2004-01-15 | — | — | US | disclosed |
| US-20030187289-A1 | Biphenyl derivatives and the use thereof as integrin inhibitors | MERCK PATENT GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| EP-1311484-A1 | BIPHENYL DERIVATIVES AND THE USE THEREOF AS INTEGRIN INHIBITORS | MERCK PATENT GmbH (DE) | 2003-05-21 | — | — | EP | disclosed |
| EP-1311489-A1 | BIPHENYL DERIVATIVES AND THE USE THEREOF AS INTEGRIN INHIBITORS | MERCK PATENT GmbH (DE) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016328-A1 | BIPHENYL DERIVATIVES AND THE USE THEREOF AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016323-A1 | BIPHENYL DERIVATIVES AND THE USE THEREOF AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | CTSK 2525/4885CTSS 3083/4885CTSB 2267/4885 |
| US-20040010023-A1 | Biphenyl derivatives and the use thereof as integrin inhibitors | ITGB1, ITGB4, ITGB3 | CTSK 2109/4885CTSS 1314/4885CTSB 762/4885 |
| US-20030187289-A1 | Biphenyl derivatives and the use thereof as integrin inhibitors | ITGB1, ITGB3, ITGB2 | CTSK 2373/4885CTSS 1514/4885CTSB 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.